Background In response to the COVID-19 pandemic, the 2020–2021 residency interview process will undergo significant changes. Residency programme stakeholders would benefit from knowledge on what students and physicians expect from this process. Objective The purpose of the study was to describe and contrast the perspectives of student applicants and interviewing physicians related to the residency programme virtual interview process. Methods A survey consisting of 24 Likert statements was administered across listservs in summer 2020 to physicians (attendings and residents who interview medical students). Medical students also received an anonymous survey and were recruited via email to participate. Results A total of 155 individuals (104 fourth-year medical students and 51 physicians) completed a survey. Results showed students would prefer in-person interviews over virtual. Residency applicants had high agreement on the limited ability to fully assess the programme and city due to virtual interviews. Individuals with lower step 1 scores had higher agreement on preferring in-person interviews. Individuals in the lowest and highest scoring groups appear more worried about the representation of themselves as a result of virtual interviews. Furthermore, applicants feel that more weight will be placed on steps 1 and 2 scores and class ranks, and they may not be able to fully demonstrate their personality compared with interviewers. Conclusion The result of COVID-19 has created challenges and subsequent reshuffling of medical education requiring careful preparation and planning. This study provides insight for residency programmes to better understand the applicants’ expectations for the 2020–2021 residency interview and matching process. No data are available.

Commentary on: Maximizing Inclusiveness and Diversity through Virtual Residency Applications and Interviews by Budhu et al As medical students and residency programs enter the second year of virtual recruitment and interviews, much has been learned but much still needs to be addressed. In the recent Resident and Fellow Section of Neurology article by Budhu et...

Application for the OneBeat Virtual Residency Program 2022 is ongoing. The application deadline for this program is February 11, 2022 11:59 PM EST. Apply Now!

Background In response to the COVID-19 pandemic, the 2020–2021 residency interview process will undergo significant changes. Residency programme stakeholders would benefit from knowledge on what students and physicians expect from this process. Objective The purpose of the study was to describe and contrast the perspectives of student applicants and interviewing physicians related to the residency programme virtual interview process. Methods A survey consisting of 24 Likert statements was administered across listservs in summer 2020 to physicians (attendings and residents who interview medical students). Medical students also received an anonymous survey and were recruited via email to participate. Results A total of 155 individuals (104 fourth-year medical students and 51 physicians) completed a survey. Results showed students would prefer in-person interviews over virtual. Residency applicants had high agreement on the limited ability to fully assess the programme and city due to virtual interviews. Individuals with lower step 1 scores had higher agreement on preferring in-person interviews. Individuals in the lowest and highest scoring groups appear more worried about the representation of themselves as a result of virtual interviews. Furthermore, applicants feel that more weight will be placed on steps 1 and 2 scores and class ranks, and they may not be able to fully demonstrate their personality compared with interviewers. Conclusion The result of COVID-19 has created challenges and subsequent reshuffling of medical education requiring careful preparation and planning. This study provides insight for residency programmes to better understand the applicants’ expectations for the 2020–2021 residency interview and matching process. No data are available.

An abstract is unavailable.

Virtual interviews are likely to remain a normal part of the Match process. Learn about the four major types of virtual interviews, and how to prepare for them.

Fourth-year medical students can learn about the challenges—and advantages—of doing residency program interviews via videoconferencing.

EMRA is offering our Virtual Residency Program Fair at NO COST to EMRA medical student members. To take care of our members preparing for Match, MSIVs will have first access. As space allows, we will open registration to all medical student members.

Presearch is a decentralized search engine, powered by the community.

Event of Note: a conversation about the effects of Covid-19 on incarcerated people and those held in immigration detention.

Presearch is a decentralized search engine, powered by the community.

Oncology / Hematology Approvalls

For decades, the management of patients with advanced prostate cancer has been hormonal therapy, known as androgen deprivation therapy, which is intended to lower testosterone levels. Further incremental progress in the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC) has c …

NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.

If you have metastatic castration-resistant prostate cancer, the hormone therapy you’ve been taking is no longer controlling the disease. Here’s what you should know.

Presearch is a decentralized search engine, powered by the community.

Associate professor of medicine in the Department of Medical Oncology & Therapeutics Research, Tanya Dorff, M.D., is leading a Phase 1 clinical trial that is studying chimeric antigen receptor (CAR) T cells with specificity to prostate stem cell antigen positive (PSCA+) mCRPC.

Prostate cancer is the most common cancer among men worldwide. However, current treatments for prostate cancer patients in advanced stage often fail because of relapse. Prostate cancer stem cells (PCSCs) are resistant to most standard therapies, and are considered to be a major mechanism of cancer metastasis and recurrence. In this review, we summarized current understanding of PCSCs and their self-renewal signaling pathways with a specific focus on Wnt signaling. Although multiple Wnt inhibitors have been developed to target PCSCs, their application is still limited by inefficient delivery and toxicity in vivo. Recently, nanotechnology has opened a new avenue for cancer drug delivery, which significantly increases specificity and reduces toxicity. These nanotechnology-based drug delivery methods showed great potential in targeting PCSCs. Here, we summarized current advancement of nanotechnology-based therapeutic strategies for targeting PCSCs and highlighted the challenges and perspectives in designing future therapies to eliminate PCSCs.

Research in the last decade has clearly revealed a critical role of prostate cancer stem cells (PCSCs) in prostate cancer (PC). Prostate stem cells (PSCs) reside in both basal and luminal layers, and are the target cells of oncogenic transformation, suggesting ...

Background Autologous cellular immunotherapy or immune enhancement therapy has demonstrated some promising benefits for prostate cancer. T cell-based immunotherapy or sipuleucel-T therapy has yielded certain beneficial responses and a slight improvement on the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) as shown in some clinical trials, suggesting that prostate cancer is immunoresponsive. Methods In this study, we developed an adaptive cytokine-induced killer cell (CIK)-based immunotherapeutic application targeting the prostate cancer stem-like cells (PCSCs). In this therapeutic platform, dendritic cells (DC) were isolated from the peripheral blood mononuclear cells (PBMCs) and preloaded or sensitized with immunogenic peptides derived from two PCSC-associated cell membrane molecules, CD44 and EpCAM, followed by co-culture with the expanded peripheral blood lymphocyte (PBL)-derived CIK cells. The in vitro cytotoxic activity of DC-activated CIK cells against PCSCs was determined by CCK8 and TUNEL assays, and the in vivo anti-tumor effect of DC-activated CIK cells on prostate cancer xenograft tumors was evaluated in subcutaneous and orthotopic xenograft models. Results Our results showed that the peptide-sensitized DC-CIK cell preparation manifested significant in vitro cytotoxic activity against the PCSC-enriched prostatospheroids and also in vivo anti-tumor effect against prostate cancer xenografts derived from the PCSC-enriched prostatospheroids. Conclusions Together, our established immunogenic peptide-sensitized DC-CIK-based cell preparation platform manifests its potential immunotherapeutic application in targeting the PCSCs and also prostate cancer.

Stem Cell Cellular Therapy for Prostate Cancer Patients (Immunotherapy) Cellular therapy for prostate cancer patients also known as immunotherapy*, is a natural autologous cellular treatment that employs the use of dendritic cells, natural killer cells (NK cells), and lymphokine-activated killer cells (LAK cells) to suppress

This month is the 40th anniversary of the first unequivocal report in humans that T cells have the power to cure cancer. We look at one study's past, and continued, impact.

Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.